C4 Therapeutics, Inc. (NASDAQ:CCCC) Stock Has Average Target Price of $9.33 According to Brokerages

Posted by Brenda Bartman on Nov 8th, 2026

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $8.50.

A number of equities research analysts have recently commented on CCCC shares. JPMorgan Chase & Co. assumed coverage on shares of C4 Therapeutics in a research note on Friday, October 9th. They set an “overweight” rating and a $10.00 price objective on the stock. Guggenheim started coverage on shares of C4 Therapeutics in a research note on Friday. They issued a “buy” rating and a $6.00 target price for the company. Lake Street Capital began coverage on shares of C4 Therapeutics in a report on Wednesday, October 28th. They set a “buy” rating and a $11.00 price target on the stock. Wall Street Zen downgraded shares of C4 Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Evercore lowered shares of C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 2nd.

View Our Latest Stock Report on CCCC

Institutional Trading of C4 Therapeutics

Several institutional investors have recently bought and sold shares of CCCC. Wasatch Advisors LP grew its stake in C4 Therapeutics by 18.9% in the 2nd quarter. Wasatch Advisors LP now owns 3,522,644 shares of the company’s stock valued at $16,451,000 after acquiring an additional 560,883 shares during the period. Candriam S.C.A. raised its position in C4 Therapeutics by 53.6% during the third quarter. Candriam S.C.A. now owns 2,760,346 shares of the company’s stock worth $9,226,000 after acquiring an additional 963,409 shares during the period. Renaissance Technologies LLC lifted its holdings in C4 Therapeutics by 53.6% during the first quarter. Renaissance Technologies LLC now owns 2,461,815 shares of the company’s stock valued at $6,475,000 after purchasing an additional 859,235 shares in the last quarter. Congress Asset Management Co. lifted its holdings in C4 Therapeutics by 25.2% during the third quarter. Congress Asset Management Co. now owns 1,256,692 shares of the company’s stock valued at $4,185,000 after purchasing an additional 253,255 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in C4 Therapeutics during the second quarter valued at $2,662,000. 78.81% of the stock is owned by institutional investors and hedge funds.

C4 Therapeutics Stock Up 5.1%

Shares of CCCC opened at $3.10 on Tuesday. The company has a market capitalization of $381.39 million, a price-to-earnings ratio of -4.31 and a beta of 3.16. C4 Therapeutics has a 52 week low of $1.69 and a 52 week high of $5.17. The stock’s 50-day moving average price is $3.22 and its 200-day moving average price is $3.22.

C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. C4 Therapeutics had a negative return on equity of 37.03% and a negative net margin of 282.22%. The company had revenue of $8.47 million during the quarter, compared to analysts’ expectations of $8.52 million. As a group, equities analysts anticipate that C4 Therapeutics will post -0.81 EPS for the current fiscal year.

C4 Therapeutics Company Profile

(Get Free Report)

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary TORPEDO platform to design targeted protein degraders, which are intended to direct specific proteins to the cell’s natural disposal system rather than simply blocking their activity.

C4 Therapeutics has concentrated its research and development efforts primarily on oncology, including programs aimed at genetically defined cancers and difficult-to-treat tumors.